Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension

Abstract

<jats:p> </jats:p>

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

“…Our results showed that the switch from bosentan to macitentan resulted in improvements in relevant clinical outcomes, like WHO FC and 6MWD, with a good safety profile. These results confirm the observations of Verlinden and co‐workers in a safety and efficacy study of the transitioning from the combination of bosentan and sildenafil to alternative therapy (macitentant or riociguat), in PAH patients 24 …”

“…These results confirm the observations of Verlinden and co-workers in a safety and efficacy study of the transitioning from the combination of bosentan and sildenafil to alternative therapy (macitentant or riociguat), in PAH patients. 24 The demographic characteristics of the study population are in agreement with those reported in previous studies on the Saudi PAH population. 21,27 As usual in PH literature, we could notice a female predominance in our cohort.…”

“…20 Retrospective studies in small PAH cohorts are also available. [16][17][18]24 Still, as far as we know, this is the first prospective study addressing this analysis on an adult PAH cohort, through a multiparametric risk stratification approach, in Saudi Arabia. Similar studies, with similar inclusion criteria (up to WHO FC III), were performed with patients with intermediate risk on treatment with drugs of other classes like phosphodiesterase type 5 (PD5) inhibitors and riociguat (REPLACE and RESPITE studies).…”

“…The impact of this change has been evaluated before through prospective studies in pediatric and young adult PAH populations, 19 and in PAH‐CHD adults 20 . Retrospective studies in small PAH cohorts are also available 16–18,24 . Still, as far as we know, this is the first prospective study addressing this analysis on an adult PAH cohort, through a multiparametric risk stratification approach, in Saudi Arabia.…”

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study

“…The current evidence on the safety and efficacy of drug transition from one PAH-specific therapy to another includes the transition involving prostacyclin and its analogs ( Hoeper et al, 2002 ; Gomberg-Maitland et al, 2005 ; Ewert et al, 2007 ; Rubenfire et al, 2007 ; Sitbon et al, 2007 ; Shlobin et al, 2012 ; Bourge et al, 2013 ; Minai et al, 2013 ; Shapiro et al, 2013 ; Tamura et al, 2013 ; Frantz et al, 2014 ; Frantz et al, 2015 ; Fukumoto et al, 2015 ; Lichtblau et al, 2015 ; Chakinala et al, 2017 ; Frost et al, 2019 ) or PDE-5i ( Tay et al, 2008 ; Verlinden et al, 2020 ), but minimal data on the switch between ERA. A study reported that the switch from bosentan or sitaxentan to ambrisentan in patients with liver abnormalities is safe and can offer clinical improvement ( McGoon et al, 2009 ).…”